Needham analyst Chad Messer raised his price target on Seattle Genetics to $79 after its Q2 results, saying the sale of ADCETRIS were much higher than expected on its rapid rate of uptake in frontline Hodgins Lymphoma. Messer adds that further label expansion could come from ESCHELON-2 data expected to be out in Q4, while the company is also progressing with late stage programs such as Enfortumab Vedotoin for urothelial cancer, Tucatinib in metastatic breast cancer, and Tisotumab Vedotin in a pivotal cervical cancer study. Messer keeps his Buy rating on Seattle Genetics.